Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Moderna and Pfizer look forward to fourth dose of COVID-19 vaccine

By Brian Buntz | January 7, 2022

Vaccine

Photo by Artem Podrez from Pexels

As COVID-19 case counts surge worldwide, executives at Moderna (NSDQ:MRNA) and Pfizer (NYSE:PFE) have voiced support for additional doses of their COVID-19 vaccines.

Moderna CEO Stéphane Bancel predicted that a fourth dose would be necessary by the fall as the protection of vaccine-induced antibodies fades.

In late December, Pfizer’s chief scientific officer Dr. Mikael Dolsten said a fourth dose could be necessary in the U.S. by spring.

Pfizer executives predicted that the COVID-19 wouldn’t become endemic across the world until 2024, according to Reuters. But, that said, the emergence of variants and global vaccination could influence the trajectory of the pandemic.

Several countries are considering moving forward with providing fourth doses of COVID-19 vaccine. Israel, Canada and Chile have already begun doling out fourth doses to some individuals. In the U.S., the State of West Virginia has asked CDC for permission to do so.

Some experts have expressed skepticism about the prospect of periodic booster doses of vaccines developed based on the original strain of the novel coronavirus.

“It doesn’t make sense to keep boosting against a strain that’s already gone,” Ali Ellebedy, an immunologist at Washington University in St. Louis, told The New York Times. “If you are going to add one more dose after three, I would definitely wait for an omicron-based one.”

The World Health Organization has also resisted the idea of doling out perpetual doses of COVID-19 vaccines while a substantial number of people across the world remain unvaccinated.

The emergence of new variants could also fuel interest in a pan-coronavirus vaccine.

Researchers at the Walter Research Army Institute of Research, among others, are developing such a vaccine. Preclinical data from the WRAIR vaccine were recently published in Science Translational Medicine. However, the researchers have not yet tested the vaccine against the omicron variant.


Filed Under: Infectious Disease
Tagged With: coronavirus, covid-19, Moderna, Pfizer, vaccine
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Close-up medical syringe with a vaccine.
Six leading medical organizations sue RFK Jr. over vaccine recommendations
RFK’s new ACIP changed longstanding vaccine recommendations
Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE